• 作者：A. Andres^a ; ^{aandresgr@salud.aragon.es} ; L. Tardí ; n^a ; A. Santapau^a ; P. Razola^a ; E. Prats^a ; A. Parra^a ; M.A. Rivas^b ; P. Ruiz^b ; R. Á ; lvarez^c ; A. Camara^d ; J. Banzo^a
• 关键词：Cancer diferenciado de tiroides ; Insuficiencia renal cró ; nica terminal ; Ablació ; n de restos tiroideos con 131I ; Hormonoterapia sustitutiva recombinante humana
• 刊名：Revista Espa帽ola de Medicina Nuclear
• 出版年：2010
• 期刊代码：pca315_02126982
• 类别：med
• 出版时间：January-February 2010
• 卷：29
• 期：1
• 页码：32-35
• 文件大小：115 K

The follow-up and treatment of thyroid cancer presents several aspects subject to discussion, such as its management in patients with End-Stage Renal Failure (ESRF). We present a patient with ESRF and papillary thyroid carcinoma, which had to be coordinated among different departments (Endocrinology, Nuclear Medicine, Nephrology and Physics and Radiation Protection). Both the diagnostic scintigraphy with ¹²³I and the ablative treatment with ¹³¹I performed later were performed with the administration of rh TSH. The room in which the metabolic therapy was to be performed was prepared for the patient's periodic hemodialysis. The ¹³¹I dose used was 80%of the usual dose. This made it possible to assure the therapeutic effect and that the patient's stay in hospital would only be for 5 days. Throughout the whole diagnostic and therapeutic process, no adverse effects attributable to rh TSH or radioiodine were observed. The coordination among the departments involved enabled an effective and safe process for the patient.